JP2012502915A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502915A5
JP2012502915A5 JP2011527044A JP2011527044A JP2012502915A5 JP 2012502915 A5 JP2012502915 A5 JP 2012502915A5 JP 2011527044 A JP2011527044 A JP 2011527044A JP 2011527044 A JP2011527044 A JP 2011527044A JP 2012502915 A5 JP2012502915 A5 JP 2012502915A5
Authority
JP
Japan
Prior art keywords
epilepsy
pharmaceutically acceptable
acceptable salts
therapeutic agent
focal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011527044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502915A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/056988 external-priority patent/WO2010031054A1/en
Publication of JP2012502915A publication Critical patent/JP2012502915A/ja
Publication of JP2012502915A5 publication Critical patent/JP2012502915A5/ja
Pending legal-status Critical Current

Links

JP2011527044A 2008-09-15 2009-09-15 てんかんを治療する組成物及び方法 Pending JP2012502915A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9694008P 2008-09-15 2008-09-15
US61/096,940 2008-09-15
US18320909P 2009-06-02 2009-06-02
US61/183,209 2009-06-02
PCT/US2009/056988 WO2010031054A1 (en) 2008-09-15 2009-09-15 Compositions and methods for treating epilepsy

Publications (2)

Publication Number Publication Date
JP2012502915A JP2012502915A (ja) 2012-02-02
JP2012502915A5 true JP2012502915A5 (enExample) 2013-05-16

Family

ID=42005540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527044A Pending JP2012502915A (ja) 2008-09-15 2009-09-15 てんかんを治療する組成物及び方法

Country Status (4)

Country Link
US (3) US20110172262A1 (enExample)
EP (1) EP2340254B8 (enExample)
JP (1) JP2012502915A (enExample)
WO (1) WO2010031054A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101424514B1 (ko) 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017021951A1 (en) * 2015-08-03 2017-02-09 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Blood-brain-barrier permeability modulators and uses thereof
US11045462B2 (en) 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents
PT3562486T (pt) 2016-12-31 2024-06-12 Bioxcel Therapeutics Inc Uso de dexmedetomidina sublingual para o tratamento da agitação
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス,インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
WO2022183029A1 (en) * 2021-02-26 2022-09-01 Bioxcel Therapeutics, Inc. Methods and compositions for treating agitation
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3847770A (en) 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
US3959470A (en) 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4687610A (en) 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5602124A (en) 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
RU2140417C1 (ru) * 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
NZ501211A (en) 1999-01-29 2001-10-26 Pfizer Prod Inc Pharmaceutical composition comprising macrolide antibiotic like erythromycin and a Substance P antagonist, and method for treating cancer, bacterial and protozoal infection in non-humans
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US6383764B1 (en) * 2000-04-28 2002-05-07 The Regents Of The University Of California Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US7214673B2 (en) 2002-03-28 2007-05-08 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
WO2003086418A1 (en) 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for the treatment of cancer
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
GB0307067D0 (en) 2002-12-17 2003-04-30 Aventis Pharma Inc Use of thiazolobenzoheterocycles for treating multiple sclerosis
US20050065219A1 (en) 2003-03-27 2005-03-24 Lipton Stuart A. Treatment of demyelinating conditions
EP1623721A1 (en) 2003-05-06 2006-02-08 Ono Pharmaceutical Co., Ltd. Effector cell function inhibitor
WO2005009342A2 (en) 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
EP1727538A2 (en) * 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
RU2281085C2 (ru) 2004-05-25 2006-08-10 Закрытое акционерное общество "Мастерлек" Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
BRPI0614485A2 (pt) 2005-07-28 2011-03-29 Bristol-Myers Squibb Company tetrahidro-1h-pirido [4, 3, b] indóis substituìdos como agonistas e antagonistas receptores de serotonina
US8802707B2 (en) 2005-07-31 2014-08-12 Trevor Gordon Marshall Method of treating and/or preventing cancers using Sartans and/or Statins to modulate VDR, and/or PPAR, and/or GCR and/or CB1 receptors; in conjunction with certain bacteriostatic antibiotics
US8868172B2 (en) * 2005-12-28 2014-10-21 Cyberonics, Inc. Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
JP2010501559A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫の再発を予防するまたは遅らせるのに使用するためのビス(チオヒドラジドアミド)
AU2007297539A1 (en) 2006-09-20 2008-03-27 Medivation Neurology, Inc. Methods and compositions for treating amyotrophic lateral sclerosis (ALS)
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
CA2667553A1 (en) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
WO2008147551A1 (en) 2007-05-25 2008-12-04 Medivation Nuerology, Inc. Methods and compositions for stimulating cells
WO2008156654A2 (en) 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
GB2463833B (en) 2007-06-26 2012-02-08 Parkinson S Inst Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
EP2085120A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
WO2009135091A1 (en) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
JP2012505257A (ja) 2008-10-13 2012-03-01 バイオヴィスタ,インコーポレイテッド 多発性硬化症治療のための組成物および方法
JP2012512165A (ja) 2008-12-11 2012-05-31 バイオヴィスタ,インコーポレイテッド 四環系ピラジノインドールを用いた多発性硬化症の治療方法

Similar Documents

Publication Publication Date Title
JP2012502915A5 (enExample)
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
JP2010077141A5 (enExample)
JP2016501828A5 (enExample)
UY32599A (es) Formulación oral sólida de abt-263
JP2010174019A5 (enExample)
JP2009506117A5 (enExample)
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
JP2012255026A5 (enExample)
JP2013519675A5 (enExample)
JP2015512406A5 (enExample)
JP2009525343A5 (enExample)
JP2013542247A5 (enExample)
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
JP2011527299A5 (enExample)
JP2016517888A5 (enExample)
JP2015523407A5 (enExample)
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
FR19C1030I1 (fr) Systeme d'administration de medicament pour administrer des substances pharmaceutiquement actives pauvrement hydrosolubles
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2009537554A5 (enExample)
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique